RANKL/RANK as key factors for osteoclast development and bone loss in arthropathies

Advances in Experimental Medicine and Biology

Volumn 649, Issue , 2009, Pages 100-113

  Leibbrandt, Andreas ^a   Penninger, Josef M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAPTOR PROTEIN; BISPHOSPHONIC ACID DERIVATIVE; CALCINEURIN; CALCIUM ION; DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN KINASE P60; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TRANSCRIPTION FACTOR NFAT; PROTEIN TYROSINE KINASE;

ALBERS SCHOENBERG DISEASE; ARTHROPATHY; ARTICLE; BONE DENSITY; BONE DESTRUCTION; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVATION; GENE; GENE EXPRESSION REGULATION; HUMAN; HYPERCALCEMIA; INTRACELLULAR SIGNALING; JOINT DESTRUCTION; LIGAND BINDING; MOLECULAR INTERACTION; NONHUMAN; OSTEOCLAST DIFFERENTIATION FACTOR GENE; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPROTEGERIN GENE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B GENE; RHEUMATOID ARTHRITIS; ANIMAL; METABOLISM; OSTEOCLAST; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

MUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; BONE RESORPTION; CALCINEURIN; HUMANS; JOINT DISEASES; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; NFATC TRANSCRIPTION FACTORS; OSTEOCLASTS; OSTEOPROTEGERIN; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS C-AKT; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

EID: 70349577508     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-0298-6_7     Document Type: Article

References (104)

1. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell 2002; 2(4) :389-406. (Pubitemid 34436569)
2. Theill LE, Boyle WJ, Penninger JM. RANK-L and RANK: T-cells, bone loss and mammalian evolution. Annu Rev Immunol 2002; 20:795-823. (Pubitemid 34293440)
3. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423(6937):337-342. (Pubitemid 40852708)
4. Wada T, Nakashima T, Hiroshi N et al. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006; 12(1):17-25. (Pubitemid 43089652)
5. Tolar J, Teitelbaum SL, Orchard PJ. Osteopetrosis. N Engl J Med 2004; 351(27) :2839-2849.
6. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390(6656):175-179. (Pubitemid 27507987)
7. Wong BR, Rho J, Arron J et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-jun N-terminal kinase in T-cells. J Bioi Chern 1997; 272(40):25190-25194. (Pubitemid 27415705)
8. Lacey DL, Timms E, Tan HL et al. Osreoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93(2) :165-176. (Pubitemid 28180851)
9. Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998; 95(7) :3597-3602.
10. Yasuda H, Shima N, Nakagawa N et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139(3):1329-1337. (Pubitemid 28510154)
11. Tsuda E, Goro M, Mochizuki S et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234(1):137-142. (Pubitemid 27267548)
12. Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89(2):309-319. (Pubitemid 27199902)
13. Dougall WC, Glaccum M, Charrier K et al. RANK is essential for osteoclast and lymph node development . Genes Dev 1999; 13(18):2412-2424. (Pubitemid 29453612)
14. Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesls, lymphocyte development and lymph-node organogenesis. Nature 1999; 397(6717):315-323.
15. Li J, Sarosi I, Yan XQ et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclasrogenesis and regulation of bone mass and calcium metabolism . Proc Natl Acad Sci USA 2000; 97(4): 1566-1571. (Pubitemid 30118482)
16. Lam J, Nelson CA. Ross FP et al. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest 2001; 108(7):971-979. (Pubitemid 32946071)
17. Ito S, Wakabayashi K, Ubukara O et al. Crystal structure of the extracellular domain of mouse RANK ligand at 2.2-A resolution. J Bioi Chem 2002; 277(8) :6631-6636. (Pubitemid 34968464)
18. Wong BR, Josien R, Lee SY et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T-cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186(12):2075-2080. (Pubitemid 28013694)
19. Kartsogiannis V, Zhou H, Horwood NJ et al. Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues. Bone 1999; 25(5):525-534. (Pubitemid 29469458)
20. Fata JE, Kong YY, Li J et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 2000; 103(1):41-50.
21. Loser K, Mehling A, Loeser S et al. Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med 2006; 12(12):1372-1379. (Pubitemid 44924495)
22. Ikeda T, Kasai M, Utsuyama M et al. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 2001; 142(4) :1419-1426. (Pubitemid 32299669)
23. Ikeda T, Kasai M, Suzuki J et al. Multimerization of the receptor activator of nuclear factor-kappaB ligand (RANKL) isoforms and regulation of osteoclastogenesis, J Bioi Chern 2003; 278(47):47217-47222. (Pubitemid 37452308)
24. Suzuki J, Ikeda T, Kuroyama H et al. Regulation of osteoclastogenesis by three human RANKL isoforms expressed in NIH3T3 cells. Biochem Biophys Res Commun 2004; 314(4):1021-1027. (Pubitemid 38142386)
25. Schlondorff J, Lum L, Blobel CP. Biochemical and pharmacological criteria define two shedding activities for TRANCE/OPGL that are distinct from the tumor necrosis factor alpha convertase, J Bioi Chem 2001; 276(18):14665-14674.
26. Chesneau V, Becherer JD, Zheng Y et al. Catalytic properties of ADAM19. J Bioi Chem 2003 ;278(25) :22331-22340. (Pubitemid 36830282)
27. Lynch CC, Hikosaka A, Acuff HB et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7(5) :485-496. (Pubitemid 40719131)
28. Hikita A, Yana I, Wakeyama H et al. Negative regulation of osteoclastogenesis by ecrodornain shedding of receptor activator of NF-kappaB ligand. J Bioi Chern 2006; 281(48) :36846-36855. (Pubitemid 46049798)
29. Chan FK, Chun HJ, Zheng L et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and Signaling. Science 2000; 288(5475):2351-2354. (Pubitemid 30448156)
30. Siegel RM, Frederiksen JK, Zacharias DA et al. Fas preassociation required for apoptosis Signaling and dominant inhibition by pathogenic mutations. Science 2000; 288(5475):2354-2357. (Pubitemid 30448157)
31. Chan KF, Siegel MR, Lenardo JM. Signaling by the TNF receptor superfamily and T-cell homeostasis. Immunity 2000; 13(4):419-422.
32. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104(4) :487-501. (Pubitemid 32201945)
33. Nakagawa N, Kinosaki M, Yamaguchi K et at. RANK is the essential Signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 1998; 253(2) :395-400. (Pubitemid 29026714)
34. Williamson E, Bilsborough JM, Viney JL. Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction. J Immunol 2002; 169(7):3606-3612.
35. Josien R, Wong BR, Li HL et at. TRANCE, a TNF family member, is differentially expressed on T-cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162(5):2562-2568. (Pubitemid 29309274)
36. Gonzalez-Suarez E, Branstetter D, Armstrong A et at. RANK overexpression in transgenic mice with mouse mammary tumor virus promoter-controlled RANK increases proliferation and impairs alveolar differentiation in the mammary epithelia and disrupts lumen formation in cultured epithelial acini. Mol Cell Bioi 2007; 27(4):1442-1454. (Pubitemid 46239825)
37. Tan KB, Harrop J, Reddy M et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and nonhernaropoieric cells. Gene 1997; 204(1-2):35-46. (Pubitemid 28022168)
38. Kwon BS, Wang S, Udagawa N et at. TRI, a new member of the tumor necrosis factor receptor superfamily, induces fibroblast proliferation and inhibits osteoclastogenesis and bone resorption. FASEB J 1998; 12(10):845-854. (Pubitemid 28294674)
39. Bucay N, Sarosi I, Dunstan CR et al osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12(9):1260-1268. (Pubitemid 28213402)
40. Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osreoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247(3):610-615. (Pubitemid 28418439)
41. Hsu H, Lacey DL, Dunstan CR et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 1999; 96(7):3540-3545. (Pubitemid 29168945)
42. Hughes AE, Ralston SH, Marken J et al. Mutations in TNFRSF11A, affecting the Signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000; 24(1):45-48. (Pubitemid 30041418)
43. Whyte MP, Mills BG, Reinus WR et al. Expansile skeletal hyperphosphatasia: A new familial metabolic bone disease. J Bone Miner Res 2000; 15(12):2330-2344.
44. Whyte MP, Hughes AE. Expansile skeletal hyperphospharasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res 2002; 17(1):26-29. (Pubitemid 33150993)
45. Sobacchi C, Frattini A, Guerrini MM et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet 2007; 39(8):960-962. (Pubitemid 47185178)
46. Cundy T, Hegde M, Naot D et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet 2002; 11(18):2119-2127. (Pubitemid 34994000)
47. Chong B, Hegde M, Fawkner M et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res 2003 ; 18(12):2095-2104. (Pubitemid 37463303)
48. Inoue J, Ishida T, Tsukamoto N et at. Tumor necrosis factor receptor-associated factor (TRAF) family: Adapter proteins that mediate cytokine signaling. Exp Cell Res 2000 ; 254(1):14-24.
49. Damay BG. Haridas V, Ni J et al. Characterization of the intracellular domain of teceptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 1998: 273(32):20551-20555. (Pubitemid 28377625)
50. Wong BR. Josien R, Lee SY et al. The TRAF family of signal transducers mediates NF-kappaB activation by the TRANCE recepror. J Biol Chem 1998: 273(43):28355-28359. (Pubitemid 28496137)
51. Wong BR. Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999: 65(6):715-724. (Pubitemid 29279518)
52. Galibert L, Tomersko ME, Anderson DM et al. The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-kappaB, a member of the TNFR superfamily. J Biol Chem 1998: 273(51):34120-34127.
53. Lee ZH, Kwack K, Kim KK et al. Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. Mol Pharmacol 2000; 58(6):1536-1545.
54. Lomaga MA, Yeh WC, Sarosi I et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40 and LPS signaling. Genes Dev 1999: 13(8):1015-1024. (Pubitemid 29200984)
55. Naito A, Azuma S, Tanaka S et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999: 4(6):353-362. (Pubitemid 29359450)
56. Kobayashi N, Kadono Y, Naito A et al. Segregation of TRAF6-mediated Signaling pathways clarifies its role in osteoclastogenesis. EMBO J 2001: 20(6):1271-1280. (Pubitemid 32233967)
57. Kobayashi T, Walsh PT, Walsh MC et al. TRAF6 is a critical factor for dendritic cell maturation and development. Immunity 2003: 19(3):353-363. (Pubitemid 37153412)
58. Ye H, Arron JR, Lamothe B et al. Distinct molecular mechanism for initiating TRAF6 signalling. Nature 2002 ; 418(6896):443-447. (Pubitemid 34826847)
59. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003 ; 4(8):638-649. (Pubitemid 36917505)
60. Kanazawa K, Kudo A. TRAF2 is essential for TNF-alpha-induced osceoclastogenesis. J Bone Miner Res 2005: 20(5):840-847.
61. Kanazawa K, Azuma Y, Nakano H et al. TRAF5 functions in both RANKL- and TNFalpha-induced osreoclasrogenesis. J Bone Miner Res 2003; 18(3):443-450. (Pubitemid 36241060)
62. Wada T, Nakashima T, Oliveira-dos-Santos AJ et al. The molecular scaffold Gab2 is a crucial component of RANK signaling and osreoclasrogenesis, Nat Med 2005: 11(4):394-399. (Pubitemid 40562329)
63. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3(3):221-227.
64. Iotsova V, Caamano J, Loy J et al. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 1997; 3(11):1285-1289. (Pubitemid 27508833)
65. Franzoso G, Carlson L, Xing L et al. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 1997; 11(24):3482-3496. (Pubitemid 28023969)
66. Ruocco MG, Maeda S, Park JM et al, I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005; 201(10):1677-1687. (Pubitemid 40721011)
67. Novack DY, Yin L, Hagen-Stapleton A et al. The IkappaB function of NF-kappaB2 p100 cont rols stimulated osteoclastogenesis. J Exp Med 2003; 198(5):771-781. (Pubitemid 37087776)
68. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23(16):2838-2849. (Pubitemid 38638846)
69. Matsumoto M, Sudo T, Saito T et al. Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem 2000; 275(40):31155-31161.
70. David JP. Sabapathy K, Hoffmann O et al. JNKI modulates osceoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci 2002; 115(Pt 22):4317-4325. (Pubitemid 35460702)
71. Wagner EF. Functions of API (Fos/Jun) in bone development. Ann Rheum Dis 2002; 61(Suppl 2):ii40-42. (Pubitemid 35221711)
72. Yamamoto A, Miyazaki T, Kadono Y et al. Possible involvement of IkappaB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor kappaB ligand. J Bone Miner Res 2002; 17(4):612-621. (Pubitemid 34246636)
73. Kenner L, Hoebertz A, Beil T et al. Mice lacking JunB are osteopenic due to cell-autonomous osteoblast and osteoclast defecrs. J Cell Biol 2004; 164(4):613-623. (Pubitemid 38233322)
74. Hotokezaka H, Sakai E, Kanaoka K et al. U0126 and PD98059. specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells. J Biol Chem 2002; 277(49):47366-47372. (Pubitemid 36159251)
75. Takayanagi H, Kim S, Koga T et al. Induction and activation of the transcription factor NFATcl (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002; 3(6):889-901. (Pubitemid 35460788)
76. Takayanagi H. Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 2007; 7(4):292-304. (Pubitemid 46480961)
77. Asagiri M, Sato K, Usami T et al. Autoamplification of NFATcl expression determines its essential role in bone homeostasis. J Exp Med 2005; 202(9):1261-1269. (Pubitemid 41586956)
78. Soriano P, Montgomery C, Geske R et al. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 1991; 64(4):693-702. (Pubitemid 121001157)
79. Wong BR, Besser D, Kim N et al. TRANCE, a TNF family member, activates Akr/PKB through a signaling complex involving TRAF6 and c-Src, Mol Cell 1999; 4(6):1041-1049. (Pubitemid 30054909)
80. Nakamura I, Takahashi N, Sasaki T et al. Wortmannin, a specific inhibitor of phosphatidylinositol-3 kinase, blocks osteoclastic bone resorption. FEBS Lett 1995; 361(1):79-84.
81. Kalesnikoff J, Sly LM. Hughes MR et al. The role of SHIP in cytokine-induced signaling. Rev Physiol Biochem Pharmacol 2003; 149:87-103.
82. Sugatani T, Alvarez U, Hruska KA. PTEN regulates RANKL- and osteopcntin-stimulated signal transduction during osteoclast differentiation and cell motility. J Bioi Chem 2003; 278(7):5001-5008. (Pubitemid 36801009)
83. Takeshita S, Namba N, Zhao JJ et al. SHIP-deficient mice are severely osteoporotic due to increased numbers of hyper-resorptive osteoclasts, Nat Med 2002; 8(9):943-949. (Pubitemid 35033697)
84. Rhee SG. Regulation of phosphoinosiride-specific phospholipase C. Annu Rev Biochem 2001; 70:281-312.
85. Mao D, Epple H, Uthgenannt B et al. PL Cgamma2 regulates osteoclasrogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 2006; 116(11):2869-2879. (Pubitemid 44684472)
86. Takayanagi H. Mechanistic insight into osteoclast differentiation in osteoimmunology, J Mol Med 2005; 83(3):170-179. (Pubitemid 40487405)
87. Mocsai A, Humphrey MB, Van Ziffle JA et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 2004; 101(16):6158-6163. (Pubitemid 38520544)
88. Laurin N, Brown JP, Morissette J et al. Recurrent mutation of the gene encoding sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70(6):1582-1588. (Pubitemid 34533906)
89. Duran A, Serrano M, Leitges M et al. The atypical PKC-interacting protein p62 is an important mediator of RANK-activated osteoclastogenesis. Dev Cell 2004; 6(2):303-309. (Pubitemid 38190368)
90. Takayanagi H, Ogasawara K, Hida S et al. T-cell-mediated regulation of osteoclastogencsis by signalling cross-talk between RANKL and IFN-gamma. Nature 2000; 408(6812):600-605.
91. Takayanagi H, Kim S, Matsuo K et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002; 416(6882):744-749. (Pubitemid 34429151)
92. Syed F, Khosla S. Mechanisms of sex steroid effects on bone. Biochem Biophys Res Commun 2005; 328(3):688-696. (Pubitemid 40214350)
93. Nakamura T, Imai Y, Matsumoto T et al. Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts. Cell 2007: 130(5):811-823. (Pubitemid 47332572)
94. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001; 107(11 ):1375-1385. (Pubitemid 32522031)
95. Koseki T, Gao Y, Okahashi N et al. Role of TGF-beta family in osteoclastogenesis induced by RANKL. Cell Signal 2002; 14(1):31-36. (Pubitemid 34020826)
96. Ross FP, Teitelbaum SL. Alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 2005; 208:88-105. (Pubitemid 41746387)
97. Arai F, Miyamoto T, Ohneda O et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 1999; 190(12):1741-1754. (Pubitemid 30013841)
98. Kong YY, Feige U, Sarosi I et al. Activated T-cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402(6759):304-309.
99. Kostenuik PJ. Osteoprotegerin and RANKL regulate bone resorption, density, geomctr y and strength. Curr Opin Pharmacol 2005; 5(6):618-625. (Pubitemid 41614462)
100. Wittrant Y, Theoleyre S, Chipoy C et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 2004; 1704(2):49-57. (Pubitemid 39195349)
101. McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354(8):821-831. (Pubitemid 43290920)
102. Lane NE, Iannini M, Atkins C et al. RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(Suppl 9):S225-226.
103. Dore R, Hurd E, Palmer W et al. Denosumab increases bone mineral density in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(Suppl 9):S240.
104. Cohen SB, Valen P, Ritchlin C et al. RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: Month 6 MRI results. Arthritis Rheum 2006; 54(SuppI9):S831-832.